Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen […]
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 brain-computer interface companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
Early research shows shark antibodies carrying drugs across blood-brain barrier
Danish pharmaceutical company Lundbeck made an undisclosed milestone payment to biotech Ossianix Inc., after experiments showed that shark antibodies effectively shuttled potential drugs across the blood-brain barrier in mice. The 2 companies established a research collaboration in 2014, focusing on technology development and the delivery of antibody-based therapies across the blood-brain barrier. Get the full […]
Neural Analytics wins CE Mark for next-gen Lucid transcranial ultrasound
Neural Analytics said today it won CE Mark approval in the European Union for its next-gen Lucid M1 transcranial doppler ultrasound system. The Los Angeles-based company’s Lucid M1 is a portable all-in-one ultrasound system designed for rapid triaging and monitoring of patients with brain disorders. “The development of accurate and portable brain monitoring technology like […]
Tracking the neurodegenerative disease haunting American football
Aethlon Medical (NSDQ:AEMD) subsidiary Exosome Sciences said today that it plans to support a clinical trial involving retired NFL players to study a biomarker-based diagnostic to detect and monitor chronic traumatic encephalopathy in living people. CTE, a neurodegenerative disease found in American football players and people with a history of repetitive trauma to the head, […]
Medtronic launches trial for Visualase MRI-Guided laser ablation device in epilepsy patients
Medtronic (NYSE:MDT) said today that the 1st procedure using the Visualase MRI-Guided laser ablation system has been performed in its SLATE clinical trial evaluating the device in patients with drug-resistant mesial temporal lobe epilepsy. The trial is slated to enroll 120 patients with MTLE, the most common form of epilepsy. Researchers will observe the patients […]
Nico launches trial for brain surgery shunt
Nico Corp said today it enrolled the 1st patient in the Enrich clinical trial which aims to explore the use of its BrainPath Approach for treating intracerebral hemorrhages. The trial will examine the procedural safety as well as economic and functional benefit of early surgical removal of intracerebral hemorrhages using its BrainPath Approach system. “Our initial clinical results […]
Neurelis closes Series B for intranasal diazepam spray
Neurelis, Inc. said today that it closed a Series B financing round, led by HBM Healthcare Investments. Other investors included LYZZ Capital, which previously led a Series A funding round for the company. Neurelis will use the funds to complete clinical trials for its intranasal diazepam spray and prepare a new drug application to submit […]
Neurelis wins fast track designation from FDA for intranasal diazepam spray
Neurelis, Inc. said today that it won fast track designation from the FDA for its intranasal diazepam spray. The nasal formulation of diazepam, which is being developed for pediatric and adult epilepsy patients who experience repititive or cluster seizures, is in the final stage of clinical development, according to Neurelis. The company expects to submit […]
Stealthy NeuroVasc Technologies raises $1m
Stealthy NeuroVasc Technologies said yesterday that it raised a $1 million funding round, taking it’s total raise since last year to nearly $2.5 million. Laguna Hills, Calif.-based NeuroVasc is led by CEO Ev3 veteran Jianlu Ma, according to regulatory filings. According to the LinkedIn page of chairman Jeff Peters, the former Anulex Technologies CEO who’s also an Ev3 […]
Insightec’s Exablate wins CE Mark approval for prostate treatment, Japanese approval for essential tremor
Insightec this week announced 2 regulatory wins, receiving CE Mark approval in the European Union for its Exablate Prostate for treating locally-confined prostate cancer and Japanese approval for its Exablate Neuro for treating essential tremor. The Exablate Prostate system uses focused ultrasound to target and ablate tissue in the prostate while minimizing damage to adjacent structures, […]
Brainstorm readies phase III trial for NurOwn stem cell treatment for ALS
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it’s preparing for a phase III trial of its NurOwn stem cell treatment, after meeting with the FDA about a biologic license application. The company is developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases, such as ALS. Hackensack, N.J.-based Brainstorm is planning […]